Business Wire

Bristol Myers Squibb Presents Positive Data from Two Pivotal Phase 3 Psoriasis Studies Demonstrating Superiority of Deucravacitinib Compared to Placebo and Otezla ® (apremilast)

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE:BMY) today announced positive results from two pivotal Phase 3 trials evaluating deucravacitinib, an oral, selective tyrosine kinase 2 ...
Nasdaq

U.S. Food and Drug Administration Approves Sotyktu™ (deucravacitinib), Oral Treatment for Adults with Moderate-to-Severe Plaque Psoriasis

Pivotal Phase 3 POETYK PSO clinical trials demonstrated superior efficacy of once-daily Sotyktu over placebo and twice-daily Otezla® (apremilast) in improving skin clearance Sotyktu has a ...
MedPage Today

Deucravacitinib: Fast-Acting and Effective Out to 1 Year in Adults With Psoriasis

Deucravacitinib was effective and worked faster than placebo through 52 weeks in patients with moderate-to-severe plaque psoriasis. The phase 3 trial, which appears in the Journal of Dermatological ...
Nasdaq

New Five-Year Sotyktu (deucravacitinib) Data Show Consistent Safety and Durable Response Rates in Moderate-to-Severe Plaque Psoriasis

No new safety signals observed at Year 5 in the POETYK PSO long-term extension trial, consistent with the established Sotyktu safety profile Following five years of continuous Sotyktu treatment, ...
Monthly Prescribing Reference

FDA Approves Sotyktu for Moderate to Severe Plaque Psoriasis

The approval was based on data from the phase 3 POETYK PSO-1 and POETYK PSO-2 trials in adults with moderate to severe plaque psoriasis. The Food and Drug Administration (FDA) has approved Sotyktu ™ ...